Introduction: Nasal potential difference (NPD) test has long been used to assist in the diagnosis of CF and more recently as an outcome measure in clinical trials of new CF therapies. This test has also been adapted to the mouse nose. Objectives: We aimed at evaluating variability of the NPD measurements in CF patients displaying two severe CFTR mutations and in sex-matched healthy controls. NPD recorded from F508del-CF and normal wild-type mice were also compared. Methods: In each setting, tests were performed by a single qualified operator. In the clinical setting, the latest CFTT-TDN SOP was followed. A total of 80 tracings were obtained from 10 patients (23.2 y; range 14 to 32) and 10 healthy subjects (34 y; range 24 to 53), each tested twice, in both nostrils. Two CF and two controls were excluded from the statistical data analysis due to the presence of a single non interpretable NPD tracing (4/80, 5%). To achieve equal sample size, tests were obtained from 8 CF mice and normal wild-type. Comprehensive multivariate analysis of paired data showed a good reproducibility of NPD parameters in the clinical and the pre-clinical setting; lower variability was observed in mice. However, 95% repeatability limits of NPD parameters were large indicating a large measurement error, poor precision and low within-subject repeatability. In both settings, chloride secretion was shown to be the most reproducible and repeatable parameter.
Objective: To assess the earliest CF-related signs and symptoms in participants of a newborn screening program. Methods: On the scheduled date of sweat test and immediately before sweat sample collection, data on clinical history and physical examination were collected. CF diagnosis was confirmed by two sweat chloride measurements ( 60 mEq/L). Cases with meconium ileus were excluded. Results: 41 cases (24.1%) with a positive and 129 controls (75.9%) with a negative sweat test were included. Mean birth weight and mean age at the day of sweat test were 3,131 g and 3,276 g (p = 0.04), and 34.2 and 34.4 days old (p = 0.88) for cases and controls, respectively. Statistically significant differences were obtained from univariate analysis for weight gain lower than 300 g from birth up to the date of sweat test (22.0% vs. 6.2%, OR = 4.2, p < 0.01), salty taste of the skin (43.9% vs. 14.0%, OR = 4.7, p < 0.001), chest retractions (19.5% vs. 1.6%, OR = 14.9, p < 0.001), and voracious appetite (31.7% vs. 12.4%, 1.3, p < 0.01). After logistic regression, weight gain lower than 300 g (OR = 5.1, 95% CI, 1.6-15.6, p < 0.01), salty taste (OR = 4.4, 95% CI, 1.8-10.7, p = 0.001), and chest retractions (OR = 8.1, 95% CI, 1.4-44.9, p = 0.01) remaining as independent predictors of CF diagnosis.
Conclusions:
1. moderate-severe CF can be clinically suspected in the first weeks of life, 2. patients requiring treatment can be thus promptly identified and treated, and 3. in settings with or without newborn screening, children presenting the clinical findings described above must be referred to sweat test (among other lab exams) and/or offered a trial with pancreatic enzyme to confirm or to rule out CF. Background: Diabetic retinopathy (DR) is a serious potential complication of CFRD, and all such patients should undergo an annual screen for this, organized in the UK through the primary care national Retinopathy Screening (RS) program. However, some CFRD patients fail to attend for screening. We were interested to assess patients' understanding of DR, and the reasons for their non-attendance. Method: Using a standardized questionnaire we asked 47 CFRD patients about their understanding of DR, the importance of RS (Likert-scale 1−5), and their compliance with screening. Results: Eighty-one percent had heard about DR but only 45% admitted to formal counseling. Only 64% had attended RS in the previous year: of these, 13% had background changes and one patient (2%) had proliferative disease. Of those who did not attend, 65% said they were not asked, 24% either forgot or did not rate this an important appointment, and 12% had a recent CFRD diagnosis. Overall, 53% rated RS as very important (Likert-scale 5), 32% Likert-scale 3 or 4 and 15% were unsure. Importance of RS perceived by patients 
Conclusion:
Our results show that a significant number of CFRD patients are either not aware or lack full understanding of DR, and many do not give RS enough importance and subsequently fail to attend. We are reinforcing our RS education program by providing literature at the CF annual screen and mailshots to CFRD patients. Direct registration of patients to the national RS program may also help improve the continuity of care.
